As a tumour suppressor in GBM, F‐box protein 16 proteasomally degrades nuclear β‐catenin, and subsequently βTrCP, in a GSK‐3β‐independent manner in GBM cells, leading to inhibition of proliferation.53 Here, GSK3B is linked to glioblastoma.